Tipp

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 3/2020

Autor:: Simon Peter Gampenrieder

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Without Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

Murthy R, et al. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). Cancer Res. 2020;80(4 Supplement):GS1–01.

Krop IE, et al. Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T‑DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01). Cancer Res. 2020;80(4 Supplement):GS1–03.

Schmid P, et al. Abstract GS3-03: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. Cancer Res. 2020;80(4 Supplement):GS3–03.

Sestak I, et al. Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. Cancer Res. 2020;80(4 Supplement):GS4–03.

Li J, et al. Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial. Cancer Res. 2020;80(4 Supplement):GS1–08.

van Mackelenbergh M, et al. Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Res. 2020;80(4 Supplement):GS1–07.

Cuzick J, et al. Abstract GS4-04: Ten year results of the international breast cancer intervention study II. Cancer Res. 2020;80(4 Supplement):GS4–04.

De Censi A. Abstract ES3-3: Low dose tamoxifen and other approaches to improve chemoprevention uptake. Cancer Res. 2020;80(4 Supplement):ES3–3.

Heil J, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. Cancer Res. 2020;80(4 Supplement):GS5–03.

10.

Tasoulis MK, et al. Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis. Cancer Res. 2020;80(4 Supplement):GS5–04.

11.

Peeters M‑JTFDV, et al. Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment). Cancer Res. 2020;80(4 Supplement):GS5–06.

12.

Basik M, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020;80(4 Supplement):GS5–05.

Titel: Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)
Autor:: Simon Peter Gampenrieder
Publikationsdatum: 01.09.2020
DOI: https://doi.org/10.1007/s12254-020-00635-8
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)

Publisher’s Note

Without Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Without Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 3/2020

Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors

Rectal cancer among younger Egyptian patients—clinico-pathological features and oncologic outcomes: A single institution experience

Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring

ASH highlights 2019: “aggressive B-cell lymphoma”

Rectal cancer: latest developments and innovative new treatment concepts

The future of combination therapies in advanced melanoma